Relapsed primary spinal-cord lymphoma case report

4 evidence topics · 1 source

Objective

Location and study date

No evidence found.

Study design

Publication design

“Case report.” (opens the source at this quote in a new tab)

Eligibility criteria

Not applicable.

Treatment

Study outcomes

Rationale for using clinical response as an observed outcome

Not applicable.

Statistical analysis description

Number of participants (Planned and analyzed)

Description of analysis sets

Not applicable.

Results

Participant disposition

No evidence found.

Baseline characteristics

Presentation

“A 58-year-old male presented with progressive numbness from the neck down and neck pain.” (opens the source at this quote in a new tab)

Efficacy results

Tumor remission and follow-up

“Tumor remission was achieved with TIR, and the patient showed no relapse for 42 months after starting TIR.” (opens the source at this quote in a new tab)

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations

Summary

This single case describes remission and 42 months without reported relapse after starting tirabrutinib for primary spinal-cord lymphoma. It does not establish response frequency or comparative benefit in broader PCNSL populations.